Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Gilead Sciences, On Target. Where To Now?

|Includes: Gilead Sciences, Inc. (GILD)

On November 16, 2015, when Gilead Sciences (NASDAQ:GILD) was trading at $99 per share, we posted the following long-term downside targets for the stock:

  • $56.93
  • $49.03
  • $41.12

At the same time, we contrasted our downside targets with commentary from TheStreet.com to ensure that there was some balance to the perspective for our readers. TheStreet.com said the following of GILD:

"We rate GILEAD SCIENCES INC a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. (TheStreet.com. Gilead Sciences Stock Is the 'Chart of the Day'. Albright, Amanada. November 16, 2015. "

It is worth noting the buy rating that we gave to GILD on January 14, 2010 (seekingalpha.com/article/182592-gilead-s...). At the time, the fundamentals seemed to be supported by the technicals and warranted due diligence and possible acquisition. Subscribers to our site can gain access to our revised assessment of Gilead Sciences based on the technical attributes, which is precipitated by investor reaction to the company fundamentals.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.